Earnings Call Intelligence Subscribe
Home › Call Sheets › TMO › Q2'26
Call sheet · Q2'26

Thermo Fisher Scientific (TMO)

Q2'26 earnings call · held July 23, 2026 · compared with the Q1'26 call · management-credibility review
6/12
Disclosure score
1 high, 4 medium, 3 low flags
Financial quality
Bottom line
The sleeper story is management's systematic opacity on their best-performing segments: bioproduction gets superlatives but no growth rate, Analytical Instruments crushes margins but gets buried, and they stopped quantifying clinical research authorizations exactly when biotech funding improved. The headline beat is real but it's 100% Q2 overperformance with zero embedded improvement for H2, suggesting they don't believe their own 'strengthening activity' narrative. The binding constraint is their acquisition integration bandwidth: they need Clario and filtration deals to deliver because the organic business isn't accelerating despite the rhetoric. Marc said 'customer activity continues to strengthen across our end markets' but then guided H2 organic growth flat with Q1 at 3-4%. My view changes if Q3 organic growth exceeds 5% or if they start disclosing bioproduction and authorization growth rates again.

The 30-second version

  • Free cash flow conversion mysteriously absent while acquisitions consume capital
  • Beat-and-raise looks great but it's 100% Q2 overperformance plus acquisitions
  • Analytical Instruments posted 30% operating income growth but management buried it

What changed this quarter

MetricQ1'26Q2'26Change
Revenue$11.01B (6% YoY)$11.99B (10% YoY)+400bps acceleration
Organic Revenue Growth1% YoY5% YoY+400bps surge
Adjusted EPS$5.44 (6% YoY)$6.03 (13% YoY)+700bps acceleration
Adjusted Operating Income$2.4B (6% YoY)$2.73B (15% YoY)+900bps acceleration
Adjusted Operating Margin21.8%22.8%+100bps expansion
Life Sciences Solutions Revenue$3.2B (13% YoY)$3.5B (13% YoY)Stable high growth
Analytical Instruments RevenueFlat YoY7% YoY growth+700bps inflection
Analytical Instruments Op Margin20.7%23.0%+230bps sequential surge
Specialty Diagnostics Revenue-1% YoY6% YoY growth+700bps reversal
Lab Products & Biopharma Services Revenue7% YoY growth12% YoY growth+500bps acceleration

Accountability tracked

7 new promises made5 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full TMO Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.